Urate-Lowering Therapy and CKD Safety
If you have gout, high uric acid, and chronic kidney disease, it is natural to feel cautious about medication. You may be told that urate-lowering therapy can help prevent gout flares, but you may also wonder what it means for your kidneys over time.
Here is the simple version: kidney disease makes gout care more personal. Urate-lowering therapy may be helpful for some people with chronic kidney disease and high uric acid, but it should be started and monitored carefully by a healthcare professional.
Why chronic kidney disease and uric acid are connected
Your kidneys help clear uric acid from the body. When kidney function drops, uric acid can build up more easily. That higher uric acid can contribute to urate crystals, which are the sharp crystals behind many gout flares.
Chronic kidney disease, often shortened to CKD, can also affect medication choices. Some doses need to be adjusted. Some medicines need closer blood test monitoring. That is why people with CKD should not use a one-size-fits-all gout plan.
What the newer research found
A large 2025 study looked at adults with stage 3 or higher CKD and hyperuricemia, which means high uric acid. The researchers used data from the China Renal Data System and compared people who started urate-lowering therapy with people who received supportive care alone.
The study included 269,831 eligible person trials from 56,936 unique people. Over 3 years, the combined kidney outcome, defined as a greater than 40% drop in estimated kidney filtering function or end-stage kidney disease, was lower in the urate-lowering therapy group.
The 3-year cumulative incidence was 19.69% in the urate-lowering therapy group and 23.22% in the control group. That equals a risk difference of 3.53 percentage points favoring treatment. The study also reported lower estimated risks for end-stage kidney disease, all-cause mortality, and cardiovascular mortality in the treatment group.
Why this does not mean everyone should self-treat
This study is encouraging, but it was observational. That means it can show an association, even with careful methods, but it cannot prove cause and effect the same way a well-designed randomized clinical trial can.
The researchers also noted limits. They did not have full information on lifestyle, diet, over-the-counter medicines, or prescriptions from outside participating hospitals. The study population was mainly Chinese, so results should be checked in other populations too.
In plain language, the study adds useful evidence, but it does not replace individualized medical care.
What this means for gout patients with CKD
If you have gout and CKD, the goal is usually steady control, not quick fixes. Urate-lowering therapy, such as allopurinol or febuxostat, may be part of that plan when your doctor thinks it is appropriate.
The safest approach is to connect gout care with kidney care. Our article on why gout patient education is so important explains why understanding your own plan can make treatment less confusing.
Hydration, blood pressure control, medication review, and regular testing also matter. You can also read our guide on staying hydrated with gout, as long as your doctor has not placed you on fluid limits.
Questions to ask your doctor
- What stage of CKD do I have?
- What is my current uric acid level?
- Should I be on urate-lowering therapy?
- Which medicine fits my kidney function and heart history?
- How often should my eGFR, creatinine, liver tests, and uric acid be checked?
- Do any of my current medicines raise uric acid or affect my kidneys?
Bottom line
The newer research suggests that urate-lowering therapy may be linked with better kidney and survival outcomes in people with stage 3 or higher CKD and high uric acid. That is hopeful, but it should be handled carefully.
If you have gout, CKD, or high uric acid, do not start or stop urate-lowering medicine on your own. Work with your doctor to choose the right medicine, dose, monitoring schedule, and uric acid target for your situation.
Resources: Nie S, Zhou S, Chen R, Li L, Sun Y, Liu J, Jin L, Shao X, Pang M, Su L, Luo F, Xu X, and colleagues. “Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia.” Signal Transduction and Targeted Therapy. 2025;10:399. doi: 10.1038/s41392-025-02497-0. Available through PubMed Central as PMC12686408.